Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
about
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemiaHow I treat acute lymphoblastic leukemia in older adolescents and young adultsImproving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy.Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remissionMonitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemiaCellular immunotherapy for refractory hematological malignanciesNovel targeted therapies in acute lymphoblastic leukemia.Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy.Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development.Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemiaEfficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia.Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamineTreatment of Young Adults with Acute Lymphoblastic Leukemia.Continuing challenges and current issues in acute lymphoblastic leukemia.Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.Synergistic antileukemic therapies in NOTCH1-induced T-ALL.High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.Adult acute lymphoblastic leukemia: a cancer with no standard of care.Pre-Transplant Consolidation is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.MicroRNA expression and activity in T-cell acute lymphoblastic leukemia.Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, L-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL.Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements.Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to dateSuccessful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen
P2860
Q26764903-E2E65DCA-32CB-466B-AF9B-4478CEBF3F76Q28087589-86164017-BA8B-48CE-828B-392D8ABF977BQ36508149-F8441054-3D98-46F5-9CA9-10EAAE393FAAQ36609579-37BD6505-1BE2-4CEF-B6AA-E6124D28E0ECQ36616666-C54FA74D-9675-4934-8733-E941917838EEQ36761302-11642AEA-4AFE-4F6F-B161-621F302F2AF6Q36834079-43C300A5-E87F-4518-B51E-6120C548096BQ36945524-9869362B-AF75-44AF-BBC6-7A88BAB01119Q38120551-59DFCCAA-7E62-4223-A725-61CA99B2A691Q38269513-7CB30DD6-3809-46D6-9BAB-2CCE4AD3655AQ38282458-52258860-4635-4FBD-95A7-01BD94985ACEQ38379829-DFD48723-F6CE-48F3-A5CB-23C326B1EE8DQ38640263-B465A4B3-B4E8-4EE5-9EBB-8DA31B369812Q38872343-4CB34B0C-25D1-4965-AA61-24834EFFEB7BQ38908007-532E29D8-8ACC-46CD-9430-75C90BDC91ADQ39206217-DD7C572B-74FC-46C6-86BA-0E556BF76BACQ39366299-3C5A94AE-C465-4994-AC32-3F06351BA27AQ39396416-6846A79D-5FD2-4764-9D1B-E58751772D1CQ39401025-2FE19899-9F6A-4654-9376-6B5A938A6F03Q41724569-5ABD40D8-B92D-45B6-A238-6AFC53992139Q42051272-813F421C-69F4-4133-BB4F-E9259F481ABFQ42720673-84AAC8B5-66EA-4E86-A1AA-D5E9FF8D9326Q43552002-8B4DAC2A-6D32-4896-8F93-CD90A1B0DE55Q47564576-D44738C0-FD34-43D7-B883-106EA4FDAC18Q47706549-358B678B-2903-4EFB-9E96-029621501F28Q48320885-72F7F574-3817-427F-B968-9659C0644102Q49426279-8A777802-EAF7-44FF-87BE-719A82492C09Q50501063-87C0C5FB-256A-4FD0-B3C4-36230C30D381Q52915505-05E32A6F-325F-42E5-86CA-9CA90A62DE30Q55018427-F770323B-99E7-4AEA-8F5D-F6BE66ADD50DQ57485221-87E0D7D8-8904-47A8-A9E9-E255DE940ECAQ59126075-DEF1CD08-7344-4B0F-A1F5-84C4615FEEAA
P2860
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Dose intensification of daunor ...... Leukemia Group B Study 19802.
@ast
Dose intensification of daunor ...... Leukemia Group B Study 19802.
@en
Dose intensification of daunor ...... Leukemia Group B Study 19802.
@nl
type
label
Dose intensification of daunor ...... Leukemia Group B Study 19802.
@ast
Dose intensification of daunor ...... Leukemia Group B Study 19802.
@en
Dose intensification of daunor ...... Leukemia Group B Study 19802.
@nl
prefLabel
Dose intensification of daunor ...... Leukemia Group B Study 19802.
@ast
Dose intensification of daunor ...... Leukemia Group B Study 19802.
@en
Dose intensification of daunor ...... Leukemia Group B Study 19802.
@nl
P2093
P2860
P50
P356
P1433
P1476
Dose intensification of daunor ...... Leukemia Group B Study 19802.
@en
P2093
Bayard L Powell
Daniel J DeAngelo
Diane McDonnell
James W Vardiman
Jeffrey L Johnson
Jonathan E Kolitz
Meir Wetzler
Peter Westervelt
Richard A Larson
Richard M Stone
P2860
P356
10.1002/CNCR.27617
P407
P577
2012-06-28T00:00:00Z